Tharimmune, Inc. announced on December 6, 2024, that it has entered into a securities purchase agreement to raise gross proceeds of approximately $2.02 million through a private placement. This financing initiative is aimed at advancing the company's development programs.
The agreement involves the issuance of 961,446 shares of common stock, or common stock equivalents, to investors. Additionally, warrants to purchase up to an additional 480,723 shares of common stock were included in the offering.
This capital infusion is essential for Tharimmune, a clinical-stage biotechnology company, to fund its ongoing research and development activities and operational expenses. It helps to address the company's liquidity needs and supports the progression of its pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.